Beginner’s Guide to Research Peptides

Research peptides are synthetic short chains of amino acids — typically between 2 and 50 residues — supplied to laboratories and independent investigators for in vitro experimentation and preclinical study. The category spans a wide regulatory range. At one end are compounds with completed Phase 3 human clinical trial programs and current FDA and EMA approval in defined indications (for example, tirzepatide and semaglutide, both selective or dual incretin receptor agonists). At the other end are compounds whose published evidence base is predominantly rodent and in vitro work, with no completed Phase 3 trials in humans (for example, BPC-157 and TB-500).

All compounds supplied by Omnix Peptides are sold under the For Research Use Only (RUO) standard. Regardless of a compound’s regulatory status, the research-grade material supplied for laboratory work is not an approved drug product and is not intended for human or animal consumption, diagnostic use, or therapeutic use. Approved drug products containing the same active pharmaceutical ingredient — where they exist — are available only by prescription from a licensed healthcare provider.

This guide orients new researchers to the landscape: what a peptide is at the chemistry level, how the published evidence is structured, what the seven research categories on this site cover, what the three supplied formats (vial, capsule, spray) are used for, and how to read research papers and Certificates of Analysis with appropriate skepticism. Sections forward-link to compound hubs, goal categories, and dedicated follow-up posts on storage, paper-reading, and specific compound comparisons.

Important Note on the Evidence Base

Important note on the evidence base across this category: The published research on individual compounds described on this site spans several distinct evidence tiers, from completed Phase 3 trials in adult humans through in vitro cell-culture experiments. The strength of the conclusions that can be drawn from each compound’s literature is bounded by the design of the underlying studies. Researchers should weight evidence accordingly and consult the primary literature cited on each compound hub. Throughout this guide, the regulatory and evidence status of each compound is disclosed neutrally as part of every reference.

What Is a Peptide?

A peptide is a chain of amino acids joined by amide (peptide) bonds. By convention, chains of approximately 50 amino acids or fewer are called peptides; longer chains, particularly those that fold into stable tertiary structures, are typically called proteins. The distinction is one of length and convention rather than a sharp biochemical boundary — insulin, a 51-residue molecule, is variously called a “small protein” or a “peptide hormone” in the literature.

Most modern research peptides are produced by solid-phase peptide synthesis (SPPS), a methodology introduced by Robert Bruce Merrifield in the early 1960s and recognized with the 1984 Nobel Prize in Chemistry. SPPS enables the stepwise assembly of a defined amino acid sequence on a solid resin support, followed by cleavage, purification (typically by high-performance liquid chromatography), and characterization by mass spectrometry. The synthetic origin is significant for research-grade material: the supplied compound is a defined chemical entity with batch-specific identity and purity data, not a biological extract.

Peptide therapeutics have a long history in approved medicine. Insulin, isolated by Banting and Best in 1921 and brought to clinical use in 1922, was the first peptide drug. As of 2018, Lau and Dunn reported [1] that over 60 peptide drugs were approved in the United States and other major markets, with another 150+ peptides in active clinical development across indications including oncology, metabolic disease, infectious disease, and rare disorders. The 2020s have seen accelerated approval of incretin-class peptide agents for type 2 diabetes and chronic weight management, substantially expanding the clinical peptide landscape.

The Research Peptide Spectrum: From Phase 3-Approved to Preclinical

The 30 compounds catalogued on this site span the full regulatory and evidence spectrum. Understanding where a given compound sits on that spectrum is essential to interpreting its published literature and to scoping a research protocol appropriately.

Phase 3-approved compounds. Tirzepatide is FDA-approved for type 2 diabetes (2022) and for chronic weight management (2023), with corresponding EMA approval in both indications. In the 72-week SURMOUNT-1 obesity trial, adults without type 2 diabetes who received once-weekly subcutaneous tirzepatide achieved mean body-weight reductions of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg amounts respectively, compared with 3.1% in the placebo group [2]. Semaglutide is FDA-approved for type 2 diabetes (2017) and for chronic weight management (2021); in the 68-week STEP-1 obesity trial, adults with overweight or obesity who received once-weekly subcutaneous semaglutide 2.4 mg achieved a mean body-weight reduction of 14.9%, compared with 2.4% in the placebo group [3]. Orforglipron is an oral non-peptide small-molecule GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management in adults with obesity or overweight with weight-related comorbidities, supported by the ATTAIN Phase 3 program. Several other approved peptides — tesamorelin (HIV-associated lipodystrophy), bremelanotide (hypoactive sexual desire disorder in premenopausal women), sermorelin historically — have established but more narrowly indicated regulatory positions.

Phase 3 in development. Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist in Eli Lilly’s TRIUMPH Phase 3 program for obesity and obesity-related conditions. Phase 2 results have been published; Phase 3 readouts continue through 2025-2026.

Predominantly preclinical compounds. The largest group in the catalog by compound count consists of peptides whose published evidence base is primarily rodent injury-model work and in vitro cell-culture experiments. BPC-157 (15 amino acids, derived from a gastric protein) is the canonical example: the most cited mechanistic finding is that BPC-157 promotes angiogenesis via the VEGFR2–Akt–eNOS pathway in a rat hindlimb ischemia model [4], with subsequent rodent studies reporting accelerated tendon, ligament, and gastric-mucosal healing. There are no completed Phase 3 human clinical trials of BPC-157. The full BPC-157 mechanistic literature is summarized on the BPC-157 compound hub; similar preclinical-dominant literatures exist for TB-500, GHK-Cu, Epithalon, MOTS-c, and several others.

Both ends of this spectrum, and everything between, are supplied as research-grade material for in vitro and preclinical study. The regulatory status of an approved drug product containing the same active pharmaceutical ingredient does not transfer to research-grade material, and research-grade material is not an approved drug regardless of the active ingredient’s status elsewhere.

How the Research Is Done — A Brief Evidence Hierarchy

The published literature on any research peptide is organized along a recognizable evidence hierarchy. Understanding where a given study sits in that hierarchy is the single most important skill in reading the field critically. The categories below are not exhaustive, but they cover the bulk of what readers will encounter on individual compound hubs.

In vitro studies. Cell-culture experiments use isolated cell populations — fibroblasts, endothelial cells, hepatocytes, immune-cell subsets — cultured in defined media and exposed to the compound of interest. Outcomes are typically biochemical (signaling pathway activation, gene expression changes, protein-level changes) or phenotypic (proliferation, migration, survival under stress). In vitro work establishes mechanistic plausibility but does not establish in vivo activity. The Chang in vitro fibroblast migration study cited on the BPC-157 hub is a representative example of mechanistically informative in vitro work that complements but does not substitute for in vivo findings.

Animal-model studies. Rodent studies (typically Sprague-Dawley and Wistar rats, or C57BL/6 mice) are the workhorse of preclinical peptide research. Injury models — tendon transection, ligament transection, induced gastrointestinal lesions, hindlimb ischemia, diet-induced obesity — allow controlled investigation of compound effects on a defined biological endpoint. Animal-model findings are necessary but not sufficient for clinical translation: many compounds that show robust activity in rodent models fail to show comparable activity in human trials. Investigators in the field commonly disclose this translation gap explicitly.

Phase 1 human trials. First-in-human studies, typically conducted in small numbers of healthy volunteers, primarily evaluate safety, pharmacokinetics, and amount-tolerance. Phase 1 data establish that a compound can be administered to humans at relevant amounts without amount-limiting toxicity but do not establish efficacy. Phase 1 results for several research peptides have been published in conference proceedings or limited journal reports; full Phase 1 datasets are sometimes embedded in subsequent Phase 2 publications rather than standalone.

Phase 2 human trials. Phase 2 studies expand the participant population (typically several hundred patients with the target condition) and provide initial efficacy and concentration-response data. Phase 2 endpoints are typically biomarker-based or short-term clinical endpoints rather than hard outcomes. A successful Phase 2 program informs the design of pivotal Phase 3 trials.

Phase 3 human trials. Phase 3 studies are the pivotal trials that support regulatory approval. They are typically large (thousands of participants), multi-center, randomized, controlled, and powered to detect clinically meaningful differences on prespecified primary endpoints. The SURMOUNT and SURPASS programs for tirzepatide and the STEP program for semaglutide are contemporary examples; each program comprises multiple Phase 3 trials evaluating the compound across overlapping but distinct patient populations and indications. Phase 3 + regulatory approval represents the highest tier of evidence for any compound and is what distinguishes the small approved-drug subset of this catalog from the predominantly preclinical majority.

A separate forthcoming guide — Reading Peptide Research Papers — covers how to extract methodology, sample size, primary endpoints, and limitations from a published study. The compound hubs cite primary literature with PubMed IDs and DOIs throughout; readers are encouraged to follow citations to source papers rather than relying on summaries alone.

Research Peptide Categories by Research Goal

Compounds are organized on this site into seven research-goal categories. The categorization reflects the predominant research focus in each compound’s published literature; many compounds have secondary research applications and appear in cross-references on their compound hubs. Each category page below summarizes the compounds and links to the relevant hubs.

Recovery & Healing

Recovery & Healing covers compounds studied in injury, tissue-repair, and inflammatory-injury models. The category includes BPC-157, TB-500 (a synthetic 17-amino-acid fragment of thymosin beta-4), GHK-Cu (a copper-binding tripeptide originally isolated from human plasma), the BPC+TB combination preparation, and Thymosin Alpha-1 (a synthetic 28-amino-acid peptide investigated in immune-modulation and chronic-viral-infection contexts). The published literature for these compounds is predominantly preclinical (rodent injury models, in vitro fibroblast and endothelial assays), with isolated human clinical data for some indications.

Metabolic & Weight

Metabolic & Weight is the most regulatorily heterogeneous category in the catalog. It includes the three FDA-approved incretin-class compounds discussed above (tirzepatide, semaglutide, orforglipron), one Phase 3-active incretin-class candidate (retatrutide), and several earlier-stage compounds investigated in metabolic-disease research: 5-Amino-1MQ (a small-molecule NNMT inhibitor studied for adipose-tissue effects), Tesofensine (a centrally-acting monoamine reuptake inhibitor with completed Phase 2 obesity trials), BAM15 (a mitochondrial protonophore studied in metabolic-disease preclinical models), SLU-PP-332 (a synthetic ERR agonist in early preclinical research), MOTS-c (a 16-amino-acid mitochondrially-encoded peptide), and AOD-9604 (a synthetic C-terminal fragment of human growth hormone whose Phase IIb obesity trial program did not meet its primary efficacy endpoint).

Cognitive & Focus

Cognitive & Focus includes Selank (a synthetic heptapeptide derived from the tuftsin sequence, originally developed in the Soviet/Russian pharmacological literature) and Semax (a synthetic heptapeptide derived from adrenocorticotropic hormone, also developed in Russia). The published Selank and Semax literature draws heavily on the Russian-language pharmacology canon, with a smaller English-language translation literature. Dihexa, a synthetic angiotensin-IV analog (development code PNB-0408) investigated in preclinical models of cognitive function, is also in this category.

Longevity & Anti-Aging

Longevity & Anti-Aging covers compounds studied for cellular-aging, mitochondrial-function, and lifespan-related endpoints, predominantly in preclinical models. NAD+ (nicotinamide adenine dinucleotide) and its precursors have a substantial published literature on cellular metabolism and aging biology. Epithalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in the Russian gerontology literature. Glutathione is a ubiquitous endogenous tripeptide with an extensive antioxidant literature. MOTS-c also appears here for its mitochondrial-encoded peptide biology.

Skin & Hair

Skin & Hair centers on GHK-Cu, whose published cosmetic-science literature is among the longest-running in the peptide field (Pickart and colleagues have published on the compound since the 1970s). Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone investigated in melanocortin-system research. The category also includes the Glow Blend combination preparation.

Growth Hormone Axis

Growth Hormone Axis covers compounds that act on the somatotropic axis through several distinct mechanisms. CJC-1295 (No DAC) and Sermorelin are synthetic analogs of growth-hormone-releasing hormone (GHRH). Ipamorelin is a selective synthetic growth-hormone secretagogue acting at the ghrelin receptor. Tesamorelin is an FDA-approved GHRH analog (2010) indicated for HIV-associated lipodystrophy. IGF-1 LR3 is a synthetic long-arginine analog of insulin-like growth factor 1, downstream of the GH axis. The mechanistic and clinical literatures across these compounds differ substantially; the individual compound hubs cover the differences in detail.

Sexual Health

Sexual Health includes PT-141 (bremelanotide), a synthetic melanocortin-receptor agonist FDA-approved (2019) for hypoactive sexual desire disorder in premenopausal women, and Kisspeptin-10, a synthetic decapeptide fragment of the larger kisspeptin neuropeptide investigated for its role in hypothalamic gonadotropin regulation. Melanotan II also has historical research literature in this category through its melanocortin-receptor activity, although the compound is primarily catalogued under Skin & Hair.

Available Research Formats — Vial, Capsule, and Spray

Omnix Peptides supplies research peptides in three formats, each used in different research contexts. The format is not a clinical-route recommendation; format selection should be driven by the experimental model and the relevant administration route in the published literature for the compound under study.

• Vials (lyophilized powder for reconstitution). The vial is the canonical research format used in the majority of published preclinical and clinical peptide literature. Lyophilized powder is reconstituted in bacteriostatic water or sterile saline immediately before use in the model system. Most compounds in the catalog are supplied in vial format; many vial SKUs are available in multiple strengths (for example, BPC-157 vial in 5 mg, 10 mg, and 15 mg; tirzepatide vial in repeated administration strengths). The BPC-157 vial product page documents the lyophilized presentation and the per-batch Certificate of Analysis pattern used across the catalog.
• Capsules (oral format). Oral capsule format is used in research models evaluating gastrointestinal-localized exposure or chronic-oral-administration kinetics. For compounds with reported in vivo activity by the oral route (BPC-157 has been described in the literature as stable in human gastric juice without enzymatic degradation; Cerovecki reported ligament-healing efficacy in rats by intraperitoneal, oral, and topical routes), the capsule format enables research designs that would be impractical with the injectable vial format.
• Sprays (liquid intranasal/mucosal format). Spray formats are used in research models evaluating non-injectable mucosal delivery. The Selank and Semax compound literatures have an established intranasal-administration tradition; the BPC-157 and PT-141 spray products extend the mucosal-delivery research format to compounds whose injectable forms are more commonly studied. Spray formats are not a substitute for the canonical vial format in research designs that require precise amount control.

Every product, regardless of format, ships with the same identity and purity characterization documentation: lot-specific Certificate of Analysis with HPLC purity assessment and LC-MS identity confirmation. The COA documentation pattern is consistent across the catalog and is anchored to the supplier’s published per-batch CoA archive.

Storage and Handling — A Brief Primer

Research peptide handling protocols are bounded by the stability characteristics of the lyophilized and reconstituted forms. Two general principles apply across the catalog, with compound-specific exceptions covered on individual hub pages and product detail pages.

Lyophilized (freeze-dried) form is the stable storage form. Lyophilized peptide powder is typically stable for extended periods (months to years, compound-dependent) when stored at refrigerator (2–8°C) or freezer (−20°C or below) temperatures, protected from light and moisture. The lyophilized form is shipped in this stable presentation and should be stored at the supplier-specified temperature until immediately before reconstitution.

Reconstituted form has a substantially shorter shelf life. Once dissolved in bacteriostatic water, sterile saline, or another aqueous vehicle, peptide stability is bounded by both chemical degradation (hydrolysis, oxidation of methionine and cysteine residues, deamidation) and biological contamination risk. Reconstituted peptide is typically usable for days to weeks at refrigerator temperature, with substantial compound-to-compound variation. Single-use aliquoting from a working vial, with the remainder stored at −20°C, is a common laboratory practice for compounds expected to be used over multiple days.

A dedicated forthcoming guide — Understanding Peptide Storage and Handling — covers reconstitution diluents, single-vehicle versus split-aliquot strategies, freeze-thaw stability data where published, and laboratory-grade aseptic technique. Compound-specific storage recommendations appear on each compound hub and on the corresponding product pages.

Evaluating Research Quality

The single most consequential decision a new researcher makes is how much weight to assign to a given published claim. The quality of the underlying study determines the strength of the conclusion that can be drawn, and study quality varies substantially across the research peptide literature.

Sample size and statistical power. Small rodent studies (n = 6 to n = 12 per group is common) detect only large effects reliably. A statistically significant finding in a small study does not establish a robust effect; replication in independent studies is the standard for confidence. Conversely, large Phase 3 trials (n = 1,000+ per arm) can detect smaller effects with confidence but may report findings whose absolute magnitude is modest.

Randomization, blinding, and controls. Methodologically rigorous studies randomize subjects to treatment versus control, blind investigators to allocation where feasible, and report outcomes against a prespecified primary endpoint. Studies that lack randomization, lack blinding, or report only post-hoc subgroup findings warrant additional scrutiny.

Animal-model-to-human translation. Many compounds with robust activity in rodent injury models fail to demonstrate comparable activity in human trials. The reasons are well-characterized in the pharmacology literature: differences in receptor expression, pharmacokinetics, immune-system composition, and the artificial nature of induced injury models all contribute to translation failure. AOD-9604 is a relevant catalog example: the compound showed reproducible activity on adipose-tissue endpoints in rodent models but did not meet its primary efficacy endpoint in the published Phase IIb obesity trial. Translation failure is the rule rather than the exception across drug development; preclinical findings should be interpreted with that base-rate in mind.

Publication venue and peer review. Peer-reviewed primary research articles in established journals (New England Journal of Medicine, The Lancet, Journal of Molecular Medicine, Journal of Applied Physiology, Journal of Orthopaedic Research) have undergone independent evaluation by domain experts. Conference proceedings, preprints, and non-peer-reviewed sources do not carry the same evidentiary weight. The references section of each compound hub lists peer-reviewed primary sources with PubMed IDs and DOIs; readers are encouraged to consult source papers directly when planning a research protocol.

Frequently Asked Questions

References

1. Lau JL, Dunn MK. Therapeutic peptides: historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707. doi:10.1016/j.bmc.2017.06.052 · PubMed: 28720325
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038 · PubMed: 35658024
3. Wilding JPH, Batterham RL, Calanna S, et al; STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183 · PubMed: 33567185
4. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y · PubMed: 27847966
5. Frías JP, Davies MJ, Rosenstock J, et al; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519 · PubMed: 34170647
6. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009 · PubMed: 30473097
7. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–hormone-receptor agonist retatrutide for obesity — a Phase 2 trial. N Engl J Med. 2023;389(6):514-526. (supportive citation flagged for PMID/DOI verification in review pass)
8. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci. 2018;19(7):1987. (supportive citation flagged for PMID/DOI verification in review pass)
9. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized Phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. (supportive citation flagged for PMID/DOI verification in review pass)
10. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370. (supportive citation flagged for PMID/DOI verification in review pass)

Citations marked with the VERIFY-PMID editorial flag are supportive references identified during drafting; their PubMed IDs and DOIs are verified in the batch verification pass before publication. Citations 1–4 and 6 are verified-load-bearing references and anchor the structural argument of this guide.

For Research Use Only. The products described on this site are sold strictly for in vitro laboratory research and are not intended for human or animal consumption, diagnostic use, or therapeutic use. The published research summarized in this guide is provided as scientific reference material. Where compounds described in this guide have approved drug products in defined indications, those approved drug products are available only by prescription from a licensed healthcare provider and are distinct from the research-grade material supplied here. Nothing on this page constitutes medical advice, a therapeutic claim, or a recommendation for any use outside of a properly resourced and ethically reviewed research setting.